immunomodulatory peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
== Business development == In 2002, BioMarin acquired Glyko Biomedical. In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse. In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia. In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
The Sudetenland ( soo-DAY-tən-land, German: [zuˈdeːtn̩ˌlant]; Czech and Slovak: Sudety) is the historical German name for the northern, southern, and western areas of former Czechoslovakia which were inhabited primarily by Sudeten Germans. These German speakers had predominated in the border districts of Bohemia, Moravia, and Czech Silesia since the Middle Ages. The word Sudetenland did not come into being until the early part of the 20th century and did not come to prominence until almost two decades into the century, after World War I, when Austria-Hungary disintegrated and the Sudeten Germans found themselves living in the new country of Czechoslovakia. The Sudeten crisis of 1938 was provoked by the Pan-Germanist demands of Nazi Germany that the Sudetenland be annexed to them, which happened after the later Munich Agreement. Part of the borderland was invaded and annexed by Poland. Afterwards, the formerly unrecognized Sudetenland became an administrative division of Germany. When Czechoslovakia was reconstituted after World War II, the Sudeten Germans were expelled and the region today is inhabited almost exclusively by Czech speakers. The word Sudetenland is a German compound of Sudeten, the name of the Sudeten Mountains, which run along the northern Czech border and Lower Silesia (now in Poland), and Land, meaning "country". The Sudetenland encompassed areas well beyond those mountains, however. Parts of the now-Czech regions of Karlovy Vary, Liberec, Olomouc, Moravia-Silesia, South Moravia and Ústí nad Labem are within the former Sudetenland.
Hospitalizations for suicide attempts are more frequent among women. In 2016, 47,110 women and 29,956 men were hospitalized following suicide attempts (61% women). In 2020, the figures were 47,826 women and 31,346 men (60.4% women). Suicidal ideation is also more common among women. In 2016, 5.4% of women and 4% of men reported suicidal thoughts; in 2020, the figures were 4.7% and 3.6%, respectively. Suicide mortality, however, is significantly higher among men. In 2016, 6,450 men and 1,985 women died by suicide (76% men). In 2020, there were 8,415 male and 2,790 female deaths by suicide (75% men).
Sources: en.wikipedia.org
== See also == Flags of the Soviet Republics Emblems of the Soviet Republics Commonwealth of Independent States Eurasian Economic Union National delimitation in the Soviet Union Bavarian Soviet Republic Hungarian Soviet Republic Slovak Soviet Republic Limerick Soviet Paris Commune Provisional Polish Revolutionary Committee (Polish SSR) Republics of Russia Federal subjects of Russia Post-Soviet states (former Soviet Republics)
In the two crystal structures of normal human G6P, Pro172 is seen exclusively in the cis conformation, while in the crystal structure of one disease causing mutant (variant Canton R459L), Pro172 is seen almost exclusively in the trans conformation.
== Origin == The tobacco etch virus encodes its entire genome as a single massive polyprotein (350 kDa). This is cleaved into functional units by the three proteases: P1 protease (1 cleavage site), helper-component protease (1 cleavage site) and TEV protease (7 cleavage sites). The native TEV protease also contains an internal self-cleavage site. This site is slowly cleaved to inactivate the enzyme (the physiological reason for this is unknown).
Sources: en.wikipedia.org
The molar mass M(X) of atoms of an element X is given by the relative atomic mass Ar(X) of the element multiplied by the molar mass constant, Mu, which (for all practical purposes) is equal to 1 g/mol: M(X) = Ar(X) ⋅ Mu. For normal samples from Earth with typical isotope composition, the atomic weight can be approximated by the standard atomic weight or the conventional atomic weight.
Mary Osborn and Klaus Weber wrote a classic paper in biochemistry on determination of the molecular weight of a protein via SDS polyacrylamide gel electrophoresis, published in 1969 in Journal of Biological Chemistry. They knew that in 1967 Shapiro, Vinuela, and Maisel had shown that electrophoresis of proteins along with Sodium Dodecyl Sulfate (SDS) in polyacrylamide gels (PAGE) could separate the tested polypeptide chains by molecular weight. To see if this method applied to proteins of various sizes and shapes, Osborn and Weber took 40 known proteins, including globular and filamentous proteins, analyzed them via SDS PAGE, and plotted the logarithms of their molecular weights against their electrophoretic mobilities. The results showed convincingly that "the good resolution and the fact that an estimate of the molecular weight can be obtained within a day, together with the small amount of protein needed, makes the method strongly competitive with others commonly employed." This method has been used extensively by biochemists in all kinds of studies involving protein purification and identification as part of the process.
== Biosynthesis == The biosynthesis of eugenol begins with the amino acid tyrosine. L-tyrosine is converted to p-coumaric acid by the enzyme tyrosine ammonia lyase (TAL). From here, p-coumaric acid is converted to caffeic acid by p-coumarate 3-hydroxylase using oxygen and NADPH. S-Adenosyl methionine (SAM) is then used to methylate caffeic acid, forming ferulic acid, which is in turn converted to feruloyl-CoA by the enzyme 4-hydroxycinnamoyl-CoA ligase (4CL). Next, feruloyl-CoA is reduced to coniferyl aldehyde by cinnamoyl-CoA reductase (CCR). Coniferyl aldehyde is then further reduced to coniferyl alcohol by cinnamyl-alcohol dehydrogenase (CAD) or sinapyl-alcohol dehydrogenase (SAD). Coniferyl alcohol is then converted to an ester in the presence of the substrate CH3COSCoA, forming coniferyl acetate. Finally, coniferyl acetate is converted to eugenol via the enzyme eugenol synthase 1 and the use of NADPH. Eugenol is a metabolite of caleicine, the active compound found in Calea ternifolia, and is thought to cause the sedative and hallucinogenic state C. ternifolia can induce.
Richard Stephen Baldock. For services to the community in Over Wallop, Hampshire. Frank Keith Ball. Poppy Appeal Collector, Royal British Legion. For voluntary service to Veterans. Michael Lawrence Ballinger. For services to the community in Wickford and District, Essex. Sean Balmer. Coach, Cockermouth Swimming Club. For services to Swimming in Cumbria. Ian John Barnaby. Crew and Navigator, Torbay Lifeboat Station, Royal National Lifeboat Institution. For voluntary services to Maritime Safety. Robert Smart Barnes. Pipe Major, Methil and District Pipe Band. For services to Young People and to the community in Levenmouth, Fife. Wendy Angharad Barnett. Guide Leader. For services to Girlguiding and to the community in Milford Haven, Pembrokeshire. Elaine Phyllis Paterson Barnwell. Fundraiser, Royal Marines Association - The Royal Marines Charity. For Charitable Services. Dr. Michael Bartlett. Medical Educator, Hywel Dda Health Board and the Royal National Lifeboat Institution. For services to Medical Education. Kirstie Louise Baughan. Social Worker, Central Bedfordshire Council. For services to Social Work. Martin James Bazeley. For services to the community in Southwick, Hampshire. Valerie Beattie. For services to the community in County Antrim. Christine Ann Beech. Guide Leader, 1st Long Lawford Brownies, Warwickshire. For services to Young People. Andrew Colin Beevers. For services to Bell Ringing and to the community in Ecclesfield, South Yorkshire. Sheila May Betts. Chair and Volunteer, The Jarman Centre, Girlguiding Cambridgeshire East. For services to Young People.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.